Prominent Activist Investor Exits Bayer Stake at Significant Loss

Inclusive Capital exits Bayer after failed breakup campaign, taking a €90M loss. The sale pressures the stock as legal and financial challenges loom.

In a decisive move, Jeff Ubben's investment firm, Inclusive Capital Partners, has divested its entire stake in pharmaceutical and life sciences giant Bayer AG. The exit comes at a substantial financial loss, with the sale price approximately 25% below the firm's initial entry point in early 2023. The transaction involved roughly 8.5 million shares changing hands for €318 million, representing a shortfall of nearly €90 million compared to the original investment. This marks an inglorious conclusion for an activist investor who once aggressively pushed for a swift corporate transformation at the German conglomerate.

Strategic Retreat After Failed Campaign

Jeff Ubben, founder of Inclusive Capital and a well-known figure in activist investing, played a significant role in shaping Bayer's recent governance. He was instrumental in advocating for the replacement of former CEO Werner Baumann and consistently called for a breakup of the company's diversified structure. Neither initiative yielded the transformative results Ubben had sought. His successor, Bill Anderson, suspended the strategic review for a split and is instead pursuing a different operational restructuring path.

While Ubben will retain his seat on Bayer's supervisory board until 2028, his investment firm is reportedly planning a full wind-down. The investor had already notified clients in November 2023 of his intention to liquidate several funds. Market analysts interpret this block trade as a clear signal that Ubben sees limited near-term upside potential in Bayer's share price.

Technical and Fundamental Headwinds Converge

The timing of the sale adds pressure during a technically fragile period for the stock. The shares had just crossed above their 100-day moving average on March 23, but the block sale promptly pushed the price back below that level. Currently, with a Relative Strength Index (RSI) reading of 16.5, the stock signals deeply oversold conditions, while trading about 11% below its 50-day average.

Fundamentally, challenges persist. The company's 2026 earnings forecast fell short of market expectations, and free cash flow for 2025 declined by 32.9% to €2.08 billion. With approximately 65,000 Roundup liability lawsuits still pending, 2026 is projected to see negative free cash flow. Bayer's net financial debt recently stood at close to €30 billion.

Two Critical Events Loom in Q2

The stock's trajectory in the coming months will be heavily influenced by two key events. On April 27, oral arguments begin before the U.S. Supreme Court to determine whether federal law preempts state-law claims alleging a failure to warn about the risks of Roundup. A favorable ruling—expected in the latter half of June—could invalidate a substantial portion of future litigation. An unfavorable outcome may render the existing settlement fund insufficient to cap long-term liability risks.

Shareholders will vote on a proposed dividend of €0.11 per share at the Annual Stockholders' Meeting on April 24. First-quarter results are scheduled for release on May 12. Until then, Bayer's equity remains caught between operational restructuring, legal uncertainty, and the aftermath of a high-profile investor's departure.